J Alzheimers Dis Parkinsonism 2017, 7:6(Suppl) DOI: 10.4172/2161-0460-C1-034

9th International Conference on

ALZHEIMER'S DISEASE & DEMENTIA

October 16-18, 2017 | Rome, Italy

Predictive molecular diagnosis of Alzheimer's Dementia: Towards new clinical models for preventive treatment

Jens Wiltfang Georg August University Göttingen, Germany

There is an unmet need for rst preventive, that is disease-modifying, treatments of Alzheimer's dementia (AD). However, preventive treatment calls for predictive diagnosis since novel preventive treatment options can only be o ered if patients are identied during preclinical stages of the incipient AD. Per denition, a preclinical stage can not be detected by clinical tools and accordingly, patients at high risk for later AD have to be identied by biomarker guided predictive diagnostics. e presentation will demonstrate that patients with preclinical AD can meanwhile be identied within the clinically heterogenous cohort of Mild Cognitive Impairment (MCI) with positive and negative predictive values of at least 90% by a multiparameter biomarker approach relying on CSF dementia biomarkers, MRI volumetry and/or F18-Amyloid-PET. In view of a prevalence of approximately 20% of preclinical AD within the MCI risk cohort the latter predictive values are clinically signicant. Morevover, it will be critically discussed in how far rst blood-based assays may support the identication of preclinical AD. Finally, the presentation will exemplify that novel diagnostic targets may indicate promising novel therapeutic targets.

Jens.Wiltfang@med.uni-goettingen.de